Regenxbio (Regenxbio) Other Operating Expense : $0.40 Mil (TTM As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Regenxbio Other Operating Expense?

Regenxbio's Other Operating Expense for the three months ended in Dec. 2023 was $0.12 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 was $0.40 Mil.

Regenxbio's quarterly Other Operating Expense increased from Jun. 2023 ($0.03 Mil) to Sep. 2023 ($0.22 Mil) but then declined from Sep. 2023 ($0.22 Mil) to Dec. 2023 ($0.12 Mil).

Regenxbio's annual Other Operating Expense declined from Dec. 2021 ($-2.24 Mil) to Dec. 2022 ($-6.68 Mil) but then increased from Dec. 2022 ($-6.68 Mil) to Dec. 2023 ($0.40 Mil).

Regenxbio Other Operating Expense Historical Data

The historical data trend for Regenxbio's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenxbio Other Operating Expense Chart

Regenxbio Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Operating Expense

Get a 7-Day Free Trial

-0.01

7.98

-2.24

-6.68

0.40

Regenxbio Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Other Operating Expense	Get a 7-Day Free Trial															-7.38	0.03	0.03	0.22	0.12

Regenxbio Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.40 Mil.

Regenxbio Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Regenxbio's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Regenxbio (Regenxbio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenxbio Inc (NAS:RGNX) » Definitions » Other Operating Expense

Comparable Companies

Traded in Other Exchanges

RB0:Germany

Address

9804 Medical Center Drive, Rockville, MD, USA, 20850

Website

https://www.regenxbio.com

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa).

Executives

Kenneth T. Mills	director, officer: See Remarks	C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Vittal Vasista	officer: See Remarks	C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Jennifer Zachary	director	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Steve Pakola	officer: Chief Medical Officer	C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Allan M. Fox	director, 10 percent owner	C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Jean Bennett	director	C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
George V Migausky	director	C/O DYAX CORP., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Patrick J. Christmas	officer: Senior VP, General Counsel	C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Curran Simpson	officer: SVP of Technical Operations	C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Hayden Donald J Jr	director	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Olivier Danos	officer: Chief Scientific Officer	C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Luke M Beshar	director	550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Stephen Yoo	officer: Chief Medical Officer	C/O REGENXBIO INC,, 9600 BLACKWELL ROAD, SUITE 210, ROCKVILLE MD 20850
Alexandra Glucksmann	director	C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Daniel Tasse	director	C/O IKARIA, INC., 6 STATE ROUTE 173, CLINTON NJ 08809